Newbury Pharmaceuticals AB (NEWBRY) - Net Assets
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has net assets worth Skr31.30 Million SEK (≈ $3.37 Million USD) as of February 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr77.26 Million ≈ $8.31 Million USD) and total liabilities (Skr45.96 Million ≈ $4.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Newbury Pharmaceuticals AB tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr31.30 Million |
| % of Total Assets | 40.51% |
| Annual Growth Rate | 10.51% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44.69 |
Newbury Pharmaceuticals AB - Net Assets Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Newbury Pharmaceuticals AB to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual net assets of Newbury Pharmaceuticals AB from 2021 to 2024. For live valuation and market cap data, see NEWBRY stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-08-31 | Skr51.92 Million ≈ $5.59 Million |
+5.14% |
| 2023-08-31 | Skr49.38 Million ≈ $5.31 Million |
-28.20% |
| 2022-08-31 | Skr68.77 Million ≈ $7.40 Million |
+78.77% |
| 2021-08-31 | Skr38.47 Million ≈ $4.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Newbury Pharmaceuticals AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr774.00K | 1.49% |
| Other Components | Skr51.14 Million | 98.51% |
| Total Equity | Skr51.92 Million | 100.00% |
Newbury Pharmaceuticals AB Competitors by Market Cap
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rossi Residencial S.A
SA:RSID3
|
$6.29 Million |
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
$6.29 Million |
|
Ecoslops SA
PA:ALESA
|
$6.30 Million |
|
Rockworth Public Company Limited
BK:ROCK
|
$6.30 Million |
|
PLENUM AG NA O.N.
F:PLEK
|
$6.28 Million |
|
Digitalist Group Oyj
HE:DIGIGR
|
$6.28 Million |
|
Strategic Energy Resources Limited
F:EB8
|
$6.28 Million |
|
NGS Group AB (publ)
ST:NGS
|
$6.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Newbury Pharmaceuticals AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 49,380,000 to 51,917,000, a change of 2,537,000 (5.1%).
- Net loss of 15,405,000 reduced equity.
- New share issuances of 18,162,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-15.40 Million | -29.67% |
| Share Issuances | Skr18.16 Million | +34.98% |
| Other Changes | Skr-220.00K | -0.42% |
| Total Change | Skr- | 5.14% |
Book Value vs Market Value Analysis
This analysis compares Newbury Pharmaceuticals AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-08-31 | Skr2.45 | Skr1.92 | x |
| 2022-08-31 | Skr3.52 | Skr1.92 | x |
| 2023-08-31 | Skr2.53 | Skr1.92 | x |
| 2024-08-31 | Skr2.42 | Skr1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Newbury Pharmaceuticals AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.83%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.75x
- Recent ROE (-29.67%) is below the historical average (-26.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -14.45% | -196.43% | 0.07x | 1.11x | Skr-9.40 Million |
| 2022 | -21.33% | -265.90% | 0.06x | 1.26x | Skr-21.54 Million |
| 2023 | -39.35% | -189.28% | 0.14x | 1.48x | Skr-24.37 Million |
| 2024 | -29.67% | -41.83% | 0.41x | 1.75x | Skr-20.60 Million |
Industry Comparison
This section compares Newbury Pharmaceuticals AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $249,457,715
- Average return on equity (ROE) among peers: -211.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Newbury Pharmaceuticals AB (NEWBRY) | Skr31.30 Million | -14.45% | 1.47x | $6.28 Million |
| BioGaia AB (publ) (BIOG-B) | $132.42 Million | 27.28% | 0.17x | $1.25 Billion |
| Enzymatica publ AB (ENZY) | $124.97 Million | -36.32% | 0.26x | $65.83 Million |
| Enorama Pharma AB (ERMA) | $1.78 Million | -1345.02% | 22.02x | $2.69 Million |
| Gabather AB (publ) (GABA) | $33.19 Million | -23.79% | 0.05x | $2.48 Million |
| Klaria Pharma Holding AB (KLAR) | $69.42 Million | -77.12% | 0.70x | $20.99 Million |
| Moberg Pharma AB (publ) (MOB) | $15.23 Million | -232.05% | 0.48x | $46.74 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $77.75 Million |
| Orexo AB (ORX) | $58.90 Million | -217.83% | 12.35x | $79.38 Million |
| Swedish Orphan Biovitrum AB (publ) (SOBI) | $1.71 Billion | 10.32% | 0.60x | $16.38 Billion |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.